Growth Hormone Secretagogues: GHRH Analogs vs Ghrelin Agonists

Growth hormone secretagogue is an umbrella term covering any compound that stimulates the pituitary gland to release growth hormone, but the peptides commonly grouped under this label work through two mechanistically distinct receptor systems. Growth hormone releasing hormone, or GHRH, analogs act on the GHRH receptor. Ghrelin receptor agonists, sometimes called growth hormone releasing peptides, act on a completely separate receptor called the growth hormone secretagogue receptor, or GHS-R.

Both pathways converge on the same somatotroph cells in the anterior pituitary, but they use different intracellular signaling cascades, which is why research protocols frequently combine one compound from each family to produce a larger pulse of growth hormone release than either would produce alone.

GHRH analogs mimic the natural hypothalamic hormone that signals the pituitary to synthesize and release growth hormone. Natural GHRH has a very short half-life, so research analogs are modified to extend activity.

This family activates the GHS-R receptor, the same receptor that the appetite hormone ghrelin naturally activates, which is part of why compounds in this class are also associated with appetite stimulation in research literature.

Because GHRH analogs and ghrelin receptor agonists work through separate receptors and signaling cascades, their effects on growth hormone pulse amplitude are frequently reported as additive or synergistic when studied together, compared to either compound alone. This is the rationale behind combination protocols such as CJC-1295 paired with ipamorelin that appear throughout the peptide research literature.

Growth hormone release is governed by a three way interaction in the hypothalamus and pituitary. Growth hormone releasing hormone stimulates somatotroph cells to synthesize and release growth hormone. Somatostatin, released from a separate hypothalamic population, inhibits that release. Ghrelin, produced largely in the stomach, acts on the growth hormone secretagogue receptor to amplify release and to suppress somatostatin tone.

The interplay of stimulation and inhibition is what makes secretion pulsatile rather than continuous. Pulses are largest during slow wave sleep and are shaped by nutritional state, exercise and age. Downstream, growth hormone acts on hepatocytes and peripheral tissues to induce insulin like growth factor 1, which mediates many of the anabolic effects and also feeds back to suppress further growth hormone release.

Because the loop remains intact under secretagogue stimulation, secretagogue research is mechanistically distinct from administering recombinant growth hormone directly, which bypasses the loop entirely.

GHRH analogs act on the GHRH receptor, a class B GPCR on somatotrophs that couples to cyclic AMP and drives both synthesis and release of stored growth hormone. Their action is constrained by somatostatin tone, so the same input produces a larger response when somatostatin is low.

Ghrelin receptor agonists act on GHSR-1a, a class A GPCR that couples primarily to phospholipase C and calcium signaling. This receptor has notably high constitutive activity, meaning it produces signal even without ligand, which is one reason inverse agonists at this receptor are studied separately.

Selectivity within the ghrelin receptor family is the main axis of difference between older and newer compounds. Earlier growth hormone releasing peptides showed appreciable cross activity at receptors driving cortisol and prolactin release. Later compounds were selected for reduced cross activity, which is the primary rationale given in the literature for preferring them as research tools when the goal is to isolate the growth hormone axis.

IGF-1 is the most commonly reported downstream marker in this literature because it integrates growth hormone exposure over roughly a day, whereas a single growth hormone measurement captures only where the sampling happened to fall within a pulse.

That convenience carries caveats. Most circulating IGF-1 is bound to IGF binding protein 3 and the acid labile subunit, so total IGF-1 reflects binding protein status as well as production. Hepatic function, nutritional intake and age all shift the relationship between growth hormone exposure and measured IGF-1. Reference ranges are strongly age dependent, which makes absolute values across differently aged cohorts difficult to compare without standardization.

Growth hormone released from the pituitary travels to the liver, where it stimulates production of insulin-like growth factor 1, or IGF-1. Much of the tissue-level activity attributed to growth hormone secretagogues in research contexts, including effects on protein synthesis and connective tissue, is understood to be mediated through this downstream IGF-1 signaling rather than growth hormone acting directly on peripheral tissue.